ABV-1527

**ABV-1527** is an investigational ovarian-cancer combination-therapy program originally included in a May 2017 global co-development agreement between American BriVision and Rgene. Public filings identify it only as an \"Ovary Cancer Combination Therapy\"; they do not disclose its active components, molecular modality, biological target, mechanism of action, dosage form, route of administration, manufacturing details, or clinical phase. In November 2020, the parties amended their agreement to remove ABV-1527 from the assets covered by that co-development arrangement. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1173313/000121390018004408/f10kt2017_americanbrivision.htm))